enVista Envy Hydrophobic Acrylic Intraocular Lens
Bausch + Lomb, Inc. · Decision date Sep 30, 2026
What did the FDA decide?
This record describes a 30-day notice supplement (S008) to PMA P240005 for the enVista Envy Hydrophobic Acrylic Intraocular Lens, a multifocal intraocular lens under product code MFK. The listed change is a process change at the manufacturer level: adding a new ISO Class 7 manufacturing cleanroom at the Clearwater, Florida facility. The notice does not state which product lines the cleanroom will serve or when production there begins.
The S008 identifier ties this notice to the earlier P240005 approval rather than establishing a separate approval of the whole lens system. A cleanroom addition is a facility and process detail; the filing's stated purpose does not by itself demonstrate safety or clinical effectiveness, and it does not describe any new indication, design change, or trial.
FDA approval order statement
adding a new ISO Class 7 manufacturing cleanroom at the Clearwater Florida facility
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 30, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240005/S008
- Regulatory pathway
- PMA supplement
- Applicant
- Bausch + Lomb, Inc.
- Product code
- MFK
- Decision code
- OK30
- Decision date
- Sep 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, multifocal intraocular.
- Applicant
- Bausch + Lomb, Inc.
- Product code
- MFK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240005. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240005 · Original PMA
enVista Envy hydrophobic acrylic intraocular lens (IOL), enVista Envy toric hydrophobic acrylic intraocular lens (IOL)
P240005/S008 received
Application receipt date recorded by FDA.
P240005/S007 · Related supplement
enVista Envy hydrophobic acrylic intraocular lens (IOL)
P240005/S008 · FDA decision
30-Day Notice
P240005/S009 · Related supplement
enVista Envy Hydrophobic Acrylic Intraocular Lens
P240005/S010 · Related supplement
enVista Envy Hydrophobic Acrylic Intraocular Lens
Timeline entries are records held by MedtechLedger for P240005. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240005
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch + Lomb, Inc. | PMA approval | Oct 10, 2024 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Sep 3, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code MFK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ClearView HD intraocular lens (IOL)P200020/S013 | Lenstec, Inc. | PMA supplement | Oct 23, 2026 | FDA |
TECNIS Multi-focal 3-pc, Model ZMA00P080010/S032 | Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
| Rayner Intraocular Lenses , Ltd. | PMA supplement | Sep 24, 2026 | FDA | |
| Lenstec, Inc. | PMA approval | Jul 22, 2022 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA approval | Jan 16, 2009 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch + Lomb, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1400 N. Goodman St., Rochester, NY, 14609
Sources and methodology
- Original FDA record: P240005/S008
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


